SCOPUS 정보 검색 플랫폼

Clinical Infectious Diseases

Volumn 44, Issue 10, 2007, Pages 1389-1391

Reply to Chinello and Petrosillo [4]

(2) Owens Jr , Robert C a,b Nolin, Thomas D a,b

a MAINE MEDICAL CENTER (United States)

b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIINFECTIVE AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; MACROLIDE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; PYRROLE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

ELECTROCARDIOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PHYSICIAN; PRIORITY JOURNAL; QT PROLONGATION;

EID: 34248183608 PISSN: 10584838 EISSN: None Source Type: Journal
DOI: 10.1086/516613 Document Type: Letter

Times cited : (3)

References (8)

1
- 34248227454
- Chinello P, Petrosillo N. QT interval prolongation and antiretroviral treatment: another point of interest. Clin Infect Dis 2007; 44: 1388-9 (in this issue).
- Chinello P, Petrosillo N. QT interval prolongation and antiretroviral treatment: another point of interest. Clin Infect Dis 2007; 44: 1388-9 (in this issue).

2
- 33845512496
- Antimicrobial-associated QT interval prolongation: Pointes of interest
- Owens RC Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006; 43:1603-11.
- (2006) Clin Infect Dis , vol.43 , pp. 1603-1611
- Owens Jr, R.C.¹ Nolin, T.D.²

3
- 33750975066
- QTc prolongation in human immunodeficiency virus-infected persons
- Petrosillo N, Lisena FP, Chinello P. QTc prolongation in human immunodeficiency virus-infected persons. Arch Intern Med 2006; 166:2288-9.
- (2006) Arch Intern Med , vol.166 , pp. 2288-2289
- Petrosillo, N.¹ Lisena, F.P.² Chinello, P.³

4
- 7244224745
- Polypharmacy in HIV: Impact of data source and gender on reported drug utilization
- Furler MD, Einarson TR, Walmsley S, Millson M, Bendayan R. Polypharmacy in HIV: impact of data source and gender on reported drug utilization. AIDS Patient Care STDS 2004; 18: 568-86.
- (2004) AIDS Patient Care STDS , vol.18 , pp. 568-586
- Furler, M.D.¹ Einarson, T.R.² Walmsley, S.³ Millson, M.⁴ Bendayan, R.⁵

5
- 13844310308
- Blockade of HERG channels by HIV protease inhibitors
- Anson BD, Weaver JG, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet 2005; 365:682-6.
- (2005) Lancet , vol.365 , pp. 682-686
- Anson, B.D.¹ Weaver, J.G.² Ackerman, M.J.³

6
- 33744490677
- A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients
- Busti AJ, Tsikouris JP, Peeters MJ, et al. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Med 2006; 7: 317-22.
- (2006) HIV Med , vol.7 , pp. 317-322
- Busti, A.J.¹ Tsikouris, J.P.² Peeters, M.J.³

7
- 34248231953
- 21-567: Atazanavir
- 14 April, Available at:, Accessed 6 February
- Marcus KA. NDA 21-567: atazanavir. The Food and Drug Administration. 14 April 2003. Available at: http://www.fda.gov/ohrms/dockets/ac/ 03/slides/3950S1_05_FDA-Atazanavir.ppt. Accessed 6 February 2007.
- (2003) The Food and Drug Administration
- Marcus, K.N.¹

8
- 33847721472
- Prolonged QT interval and torsades de pointes associated with atazanavir therapy
- in press
- Ly T, Ruiz ME. Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Clin Infect Dis 2007; 44:e67-8 (in press).
- (2007) Clin Infect Dis , vol.44
- Ly, T.¹ Ruiz, M.E.²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.